InvivydIVVD +2.49%29 Pretax Margin % is -301.22% as of Mar. 2026. GuruFocus rates IVVD with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 946 Biotechnology companies, Invivyd ranks worse than 54.44% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Invivyd's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-41.40 Mil. Invivyd's Revenue for the
three
months ended in Mar. 2026 was $13.74 Mil. Therefore, Invivyd's pretax margin for the quarter that ended in Mar. 2026 was -301.22%.
The historical rank and industry rank for Invivyd's Pretax Margin % or its related term are showing as below:
IVVD'
s Pretax Margin % Range Over the Past 10 Years
Min: -669.42 Med: -383.84 Max: -98.25
Current: -138.9
IVVD's Pretax Margin % is ranked worse than 54.44% of 946
companies
in the Biotechnology industry
Industry Median: -90.5
vs IVVD: -138.90
Invivyd (NAS:IVVD) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Invivyd Pretax Margin % Related Terms
Invivyd Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Invivyd's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IVVD vs RCKT, LCTX, FATE: Pretax Margin % Comparison
For the Biotechnology subindustry, Invivyd's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Invivyd Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Invivyd's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Invivyd's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Invivyd (IVVD) has a Pretax Margin % of -301.22% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Invivyd and its competitors. According to the industry distribution chart, Invivyd ranks #515 out of 946 companies in the Biotechnology industry, placing it in the top 54.4%.
Is Invivyd's Pretax Margin % too high?
Invivyd's current Pretax Margin % is -301.22%. Based on the distribution chart, Invivyd ranks #515 out of 946 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Invivyd has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Invivyd's Pretax Margin % compare to RCKT and LCTX?
According to the Biotechnology industry distribution chart, Invivyd ranks #515 out of 946 companies for Pretax Margin %. This places Invivyd in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Invivyd and its competitors. Invivyd's current Pretax Margin % is -301.22%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Invivyd stock overvalued right now?
Invivyd (IVVD) has a current Pretax Margin % of -301.22%. The current Pretax Margin % is -301.22%. Invivyd's overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Invivyd (IVVD), the current Pretax Margin % is -301.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Invivyd Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of monoclonal antibody (mAb) therapies for the prevention and treatment of serious viral infectious diseases. Its lead product, PEMGARDA (pemivibart), received emergency use authorization from the U.S. FDA for the pre-exposure prevention of COVID-19 in certain immunocompromised individuals. The company is also developing next-generation antibody candidates, including VYD2311 for COVID-19 and VBY329 for RSV infections, while continuing research on additional antibodies targeting other viral diseases such as measles.
29GF Score
Get the complete analysis for IVVD
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IVVD has been successfully added to your 
